These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17659340)

  • 1. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
    Browning RL; Geyer SM; Johnson AJ; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Zent CS; Bone ND; Dewald GW; Lin TS; Heerema NA; Grever MR; Kay NE; Byrd JC; Lucas DM
    Leuk Res; 2007 Dec; 31(12):1737-40. PubMed ID: 17659340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
    Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
    Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
    Awan FT; Kay NE; Davis ME; Wu W; Geyer SM; Leung N; Jelinek DF; Tschumper RC; Secreto CR; Lin TS; Grever MR; Shanafelt TD; Zent CS; Call TG; Heerema NA; Lozanski G; Byrd JC; Lucas DM
    Blood; 2009 Jan; 113(3):535-7. PubMed ID: 19008456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
    Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Dillman RO; Schreeder MT; Hon JK; Connelly EF; DePriest C; Cutter K
    Cancer Biother Radiopharm; 2007 Apr; 22(2):185-93. PubMed ID: 17600465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentostatin and rituximab in the treatment of patients with B-cell malignancies.
    Drapkin R
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):25-9. PubMed ID: 10887641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
    J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-based phase II trial of PCR for CLL/SLL patients.
    Kay NE; Shanafelt TD; Byrd JC; Grever MR
    Cancer Biother Radiopharm; 2007 Oct; 22(5):713-4; author reply 715-7. PubMed ID: 17979574
    [No Abstract]   [Full Text] [Related]  

  • 14. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
    Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
    Plander M; Skrapits J; Bozsó T; Szendrei T; Iványi JL
    Orv Hetil; 2012 Oct; 153(41):1622-8. PubMed ID: 23045312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab.
    Tsiara SN; Kapsali HD; Chaidos A; Christou L; Bourantas KL
    Acta Haematol; 2004; 111(4):185-8. PubMed ID: 15153709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
    Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
    Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.